أيفودكس إيفوسيدينيب 250 ملغ

MYR 261.33

2,000+ terjual
Harga Promosi

Farmasi fizikal Hong Kong dengan jaminan produk tulen 100%

Sorotan Produk

Ivosidenib IDH1 2018 7 ,Ivosidenib FDA IDH1 R/R AML 2021 8 ,Ivosidenib FDA IDH1 CCA

Jaminan Perkhidmatan

Penghantaran Rentas SempadanFarmasi BerlesenDisemak Ahli FarmasiJaminan Ketulenan

Spesifikasi

Spesifikasi
250mg*30 tablets

Maklumat Produk

Nama Inggeris
Ivosidenib 250mg
Nama Cina
AIVODX
Nama Generik
AIVODX

Spesifikasi

Spesifikasi
250mg*30 tablets

Butiran Penuh

Indikasi

AIVODX 1(IDH1) , FDA IDH1 (AML) • , 75 AML, AML • AML •

Mekanisme Tindakan

12.1 Mekanisme Tindakan , 1 (IDH1) (AML) , IDH1 2- (2-HG) , 1) / 2) , , IDH1 AML R132H R132C , IDH1 IDH1 R132 IDH1 2-HG

Farmakologi

12 12.1 Mekanisme Tindakan , 1 (IDH1) (AML) , IDH1 2- (2-HG) , 1) / 2) , , IDH1 AML R132H R132C , IDH1 IDH1 R132 ivosidenib IDH1 2-HG ,

Dos dan Cara Penggunaan

2 500 mg, , 2.2 2.1 IDH1 TIBSOVO [ 14.1 14.2 14.3 14.4 ] FDA AML MDS IDH1 , TIBSOVO 500 mg, [ 14.1 14.2 14.3 14.4 ] AML MDS , TIBSOVO 6 ,

Langkah Berjaga-jaga

5 Langkah Berjaga-jaga QTc QTc , , TIBSOVO 2.3,5.2 - / - , TIBSOVO 2.3,5.3 5.1 AML MDS , TIBSOVO

Interaksi Ubat

7. CYP3A4 CYP3A4 , TIBSOVO QTc 2.4 5.2 7.1 12.3 CYP3A4 TIBSOVO 7.1 12.3 CYP3A4 TIBSOVO 7.2 12.3 QTc TIBSOVO

Package Insert

Ingredients

11 TIBSOVO ivosidenib 1 (IDH1) (2S)-N-{(1S)-1-(2- )-2-[(3,3- ) ]-2- }-1-(4- -2- )-N-(5- -3- )-5- -2- C28H22ClF3N6O3, 583.0 g/mol Ivosidenib pH 1.2 7.4 TIBSOVO ivosidenib 250 mg ,

Indications

AIVODX 1(IDH1) , FDA IDH1 (AML) • , 75 AML, AML • AML •

Dos dan Cara Penggunaan

2 500 mg, , 2.2 2.1 IDH1 TIBSOVO [ 14.1 14.2 14.3 14.4 ] FDA AML MDS IDH1 , TIBSOVO 500 mg, [ 14.1 14.2 14.3 14.4 ] AML MDS , TIBSOVO 6 ,

Precautions

5 Langkah Berjaga-jaga QTc QTc , , TIBSOVO 2.3,5.2 - / - , TIBSOVO 2.3,5.3 5.1 AML MDS , TIBSOVO

Use in Pregnancy and Lactation

8.1 - ,TIBSOVO TIBSOVO , - , ivosidenib - , AUC 2 , , ,

Interaksi Ubat

7. CYP3A4 CYP3A4 , TIBSOVO QTc 2.4 5.2 7.1 12.3 CYP3A4 TIBSOVO 7.1 12.3 CYP3A4 TIBSOVO 7.2 12.3 QTc TIBSOVO

Clinical Pharmacology

12 12.1 Mekanisme Tindakan , 1 (IDH1) (AML) , IDH1 2- (2-HG) , 1) / 2) , , IDH1 AML R132H R132C , IDH1 IDH1 R132 ivosidenib IDH1 2-HG

Pharmacology and Toxicology

13 13.1 ivosidenib Ames ivosidenib ivosidenib ivosidenib , ivosidenib, 90 , ,

Clinical Studies

14 14.1 AML AML TIBSOVO (1:1) AG120-C-009,NCT03173248 146 IDH1 AML , 75 , , , (ECOG) 2 > 1.5 < 45 mL/min IDH1 Abbott RealTime™ IDH1

Ulasan Produk (0)

Filter: All Reviews
5.0★★★★★
No reviews yet for this product.

Penerangan produk

Indikasi

AIVODX 1(IDH1) , FDA IDH1 (AML) • , 75 AML, AML • AML •

Mekanisme Tindakan

12.1 Mekanisme Tindakan , 1 (IDH1) (AML) , IDH1 2- (2-HG) , 1) / 2) , , IDH1 AML R132H R132C , IDH1 IDH1 R132 IDH1 2-HG

Farmakologi

12 12.1 Mekanisme Tindakan , 1 (IDH1) (AML) , IDH1 2- (2-HG) , 1) / 2) , , IDH1 AML R132H R132C , IDH1 IDH1 R132 ivosidenib IDH1 2-HG ,

Dos dan Cara Penggunaan

2 500 mg, , 2.2 2.1 IDH1 TIBSOVO [ 14.1 14.2 14.3 14.4 ] FDA AML MDS IDH1 , TIBSOVO 500 mg, [ 14.1 14.2 14.3 14.4 ] AML MDS , TIBSOVO 6 ,

Langkah Berjaga-jaga

5 Langkah Berjaga-jaga QTc QTc , , TIBSOVO 2.3,5.2 - / - , TIBSOVO 2.3,5.3 5.1 AML MDS , TIBSOVO

Interaksi Ubat

7. CYP3A4 CYP3A4 , TIBSOVO QTc 2.4 5.2 7.1 12.3 CYP3A4 TIBSOVO 7.1 12.3 CYP3A4 TIBSOVO 7.2 12.3 QTc TIBSOVO

Maklumat tambahan

Specification

250mg*30片